WEBs Industrials XLI Defined Volatility ETF (DVIN)
Live price chart, market sentiment, and community perspectives for WEBs Industrials XLI Defined Volatility ETF (NASDAQ: DVIN).
Live price chart, market sentiment, and community perspectives for WEBs Industrials XLI Defined Volatility ETF (NASDAQ: DVIN).
On our desk, looking at the structural profile of DVIN, the numbers are alarming. With an AUM hovering around $276K to $310K and trading a mere 541 shares per day, this ETF is practically defunct. When you tack on a heavy 0.89% expense ratio and a 0.22% bid-ask spread, any theoretical defined-volatility advantage gets completely chewed up by execution costs. It is entirely uninvestable for retail capital.
Market sentiment took a definitive hit when WEBs Investments announced on August 14, 2026, that they intend to close all 11 series of their Defined Volatility Sector ETFs, including DVIN. Watching the sentiment across forums, this closure confirmation removes any lingering speculation about the fund's viability and signals a complete wind-down for this niche experiment.
From a quantitative risk perspective, DVIN shows a 1-year beta of 1.46 against its industrials peers—way higher than the typical 0.9–1.1 range—combined with weak Sharpe (0.33) and Sortino (0.68) ratios. Even though Morningstar rates its 3-year risk as Low vs category, it pairs that with Low return, reflecting poor efficiency rather than true defensive quality.
Evaluating the forward macro outlook for DVIN, the fund holds a price-to-earnings ratio of 26.62x against a category average of 24.05x. With U.S. ISM Manufacturing PMI oscillating around the 49–50 contraction-expansion boundary and the Fed rate holding at 4.25%–4.50% with minimal cuts priced in for the year, the valuation re-rating potential required for industrials to outperform is severely restricted.
As a risk manager reviewing portfolio holdings, the lack of performance data across standard windows (1M, 3M, 6M, YTD, 1Y, 3Y, 5Y) makes quantitative evaluation impossible. Furthermore, holding only 4 underlying securities while charging nearly 4 to 8 times more than passive sector competitors like XLI makes the product fundamentally flawed from a fee-to-diversification standpoint.
Explore plasma cleansing, somatic organ swaps, and BCI.